Atazanavir-d9 (BMS-232632-d9) is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selectiveHIV-1proteaseinhibitor, is the first protease inhibitor approved for once-daily administration^[1]. Atazanavir (BMS-232632) is a substrate and inhibitor ofCYP3A4, and an inhibitor and inducer ofP-glycoprotein(P-gp)^[2]. Atazanavir is also aSARS-CoV3CL^proinhibitor with anIC₅₀of 3.49 μM^[3].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

713.91

C₃₈H₄₃D₉N₆O₇

1092540-51-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.